Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ: TSHA )

1.850 +0.020 (+1.09%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
From Taysha Gene Therapies, Inc.
Via Business Wire
Executives Buy Around $62M Of 3 Stocks
The Nasdaq index jumped more than 200 points on Friday after Amazon.com, Inc. (NASDAQ: AMZN) reported better-than-expected earnings for its fourth quarter. 
Via Benzinga
Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial
Taysha Gene Therapies Inc (NASDAQ: TSHA) has  
Via Benzinga
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Plans Protocol Amendment After Patient Death In Gene Therapy Trial
Taysha Gene Therapies Inc (NASDAQ: TSHA) reported  
Via Benzinga
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis
From Taysha Gene Therapies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers TCR2 Therapeutics (NASDAQ:TCRR) s... 
Via Benzinga
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Taysha Gene Therapies, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
From Taysha Gene Therapies, Inc.
Via Business Wire
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key... 
Via Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating... 
Via Benzinga
Taysha Gene Therapies Added to the ICE Biotechnology Index
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE: 
Via Benzinga
Taysha Gene Therapies Added to the Nasdaq Biotechnology Index
From Taysha Gene Therapies
Via Business Wire
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies
Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy.... 
Via Benzinga
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript
TSHA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight
From Taysha Gene Therapies
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence
From Taysha Gene Therapies, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.